ForSight Robotics has completed a $125 million Series B funding round to advance its robotic surgical platform designed for ophthalmic procedures. The round was led by Eclipse and included participation from a strategic investor, Fred Moll—widely regarded as the father of surgical robotics—alongside Adani Group, Reiya Ventures, and other existing backers. This latest investment brings ForSight’s total funding to $195 million.
The company will use the capital to accelerate development and prepare for first-in-human clinical trials of its Oryom system, which it describes as the world’s first robotic platform for cataract and eye disease surgeries. Oryom combines AI-powered algorithms, advanced computer vision, and miniaturized mechanics to enable high-precision procedures inside the eye. Its design allows access to both anterior and posterior segments, paving the way for future applications in glaucoma and retinal surgeries.
According to Dr. Joseph Nathan, co-founder, president, and chief medical officer at ForSight Robotics, ophthalmology is poised to follow general surgery’s path in the robotics revolution. “With a comparable market size and an urgent global need, our opportunity ahead is immense. Through our latest funding round, we will bring the same level of transformative impact to eye surgery, with technology designed specifically for its unique precision and complexity,” he said.
Follow MEDWIRE.AI for updates on surgical robotics and ophthalmology innovation.
